Literature DB >> 6226738

Suppressor T cell activation by human leukocyte interferon.

H W Schnaper, T M Aune, C W Pierce.   

Abstract

Murine fibroblast interferon (IFN beta) activates murine suppressor T lymphocytes in vitro, which suppress plaque-forming cell responses by spleen cells. Suppression of human in vitro immune responses by IFN was investigated to determine whether human IFN also activates suppressor T cells. Human leukocyte IFN (IFN alpha) suppressed pokeweed mitogen-induced polyclonal immunoglobulin production by human peripheral blood mononuclear cells (PBMC) by 80 to 90% at doses of 200 to 350 U/ml. Responses by IFN alpha-treated PBMC were suppressed in a dose-dependent manner; control cultures had maximal responses on day 7. PBMC incubated with 10,000 U/ml of IFN alpha contained activated suppressor cells that decreased pokeweed mitogen-stimulated, polyclonal immunoglobulin production by autologous cells by 70 to 80%. Suppression mediated by these cells was prevented by catalase, ascorbic acid, and 2-mercaptoethanol (2-ME). In murine systems, these reagents interfere with expression of suppressor T cell activity by preventing activation of soluble immune response suppressor. Selection procedures with monoclonal antibodies identified the suppressor cell as an OKT8+ (suppressor/cytotoxic) T lymphocyte. Selected OKT8+ cells required less IFN alpha (1000 U/ml) for activation and were effective in smaller numbers than unfractionated activated PBMC. IFN alpha-activated suppressor cells also inhibited proliferation in mixed lymphocyte and mitogen-stimulated PBMC cultures; again, catalase and 2-ME blocked suppression. These results indicate that IFN alpha activates suppressor T cells in human PBMC cultures; the ability of catalase, 2-ME, and ascorbic acid to block suppression suggests that these suppressor T cells have certain similarities to IFN beta or to concanavalin A-activated murine suppressor T cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6226738

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Interfering with interferons in inflammatory bowel disease.

Authors:  S Ghosh; R Chaudhary; M Carpani; R Playford
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

2.  Steroid-sensitive mechanism of soluble immune response suppressor production in steroid-responsive nephrotic syndrome.

Authors:  H W Schnaper; T M Aune
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

3.  Identification of the lymphokine soluble immune response suppressor in urine of nephrotic children.

Authors:  H W Schnaper; T M Aune
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

4.  Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study.

Authors:  S Nikolaus; P Rutgeerts; R Fedorak; A H Steinhart; G E Wild; D Theuer; J Möhrle; S Schreiber
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

5.  Inhibitory versus stimulatory effects of natural human interferon-alpha on proliferation of lymphocyte subpopulations.

Authors:  V Holán; S Nakamura; J Minowada
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

Review 6.  Interferons in multiple sclerosis. A review of the evidence.

Authors:  H S Panitch
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

7.  Anticancer activity and chemoprevention of xenobiotic organosulfurs in preclinical model systems.

Authors:  Robert E Click
Journal:  Oncol Discov       Date:  2013

Review 8.  Inflammatory bowel disease pathobiology: the role of the interferon signature.

Authors:  Nicolaos-Panagiotis Andreou; Evangelia Legaki; Maria Gazouli
Journal:  Ann Gastroenterol       Date:  2020-02-12

Review 9.  Review: 2-mercaptoethanol alteration of in vitro immune functions of species other than murine.

Authors:  Robert E Click
Journal:  J Immunol Methods       Date:  2013-11-22       Impact factor: 2.303

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.